JP5264174B2 - スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法 - Google Patents

スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法 Download PDF

Info

Publication number
JP5264174B2
JP5264174B2 JP2007540436A JP2007540436A JP5264174B2 JP 5264174 B2 JP5264174 B2 JP 5264174B2 JP 2007540436 A JP2007540436 A JP 2007540436A JP 2007540436 A JP2007540436 A JP 2007540436A JP 5264174 B2 JP5264174 B2 JP 5264174B2
Authority
JP
Japan
Prior art keywords
active ingredient
pharmaceutical composition
particle size
saha
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2007540436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519081A (ja
Inventor
ウオン，ジーニー・チヨウ
コート，アーロン・エス
ジエンマン，エリク・エイ
ギヤラガー，キンバリー
イケダ，クレイグ
モーザー，ジヤステイン
ラジニーク，パボル
リード，ロバート・エイ
スターバツク，シンデイ
タン，シエン−シン
ワン，チンシー
コーエン，ベンジヤミン・マツクス
カポダンノ，ビンセント・アール
セル，ブライアン
ミラー，トーマス・エイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5264174(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2008519081A publication Critical patent/JP2008519081A/ja
Application granted granted Critical
Publication of JP5264174B2 publication Critical patent/JP5264174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2007540436A 2005-05-20 2006-05-16 スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法 Active JP5264174B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US60/682,875 2005-05-20
US69312805P 2005-06-23 2005-06-23
US60/693,128 2005-06-23
PCT/US2006/018795 WO2006127321A2 (en) 2005-05-20 2006-05-16 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011157930A Division JP5308486B2 (ja) 2005-05-20 2011-07-19 スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法

Publications (2)

Publication Number Publication Date
JP2008519081A JP2008519081A (ja) 2008-06-05
JP5264174B2 true JP5264174B2 (ja) 2013-08-14

Family

ID=37452585

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007540436A Active JP5264174B2 (ja) 2005-05-20 2006-05-16 スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法
JP2011157930A Active JP5308486B2 (ja) 2005-05-20 2011-07-19 スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011157930A Active JP5308486B2 (ja) 2005-05-20 2011-07-19 スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法

Country Status (20)

Country Link
US (4) US8093295B2 (OSRAM)
EP (2) EP2292221A3 (OSRAM)
JP (2) JP5264174B2 (OSRAM)
KR (2) KR100993135B1 (OSRAM)
AR (1) AR055953A1 (OSRAM)
AU (3) AU2006249440C1 (OSRAM)
BR (1) BRPI0605893A (OSRAM)
CA (1) CA2580367C (OSRAM)
CR (1) CR8912A (OSRAM)
DO (1) DOP2006000113A (OSRAM)
EC (1) ECSP077263A (OSRAM)
IL (1) IL181070A0 (OSRAM)
MA (1) MA28804B1 (OSRAM)
MX (1) MX2007002047A (OSRAM)
MY (1) MY144613A (OSRAM)
NI (1) NI200700031A (OSRAM)
NZ (2) NZ594669A (OSRAM)
PE (1) PE20061390A1 (OSRAM)
TW (2) TWI365068B (OSRAM)
WO (2) WO2006127319A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
NZ592686A (en) 2008-10-15 2012-12-21 Generics Uk Ltd Process for the preparation of vorinostat from aniline, hydroxylamine and suberic acid starting materials
WO2010061220A2 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Novel processes and pure polymorphs
CN102282126A (zh) * 2008-11-26 2011-12-14 基因里克斯(英国)有限公司 多晶型物
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
WO2018011811A2 (en) * 2016-07-13 2018-01-18 Rappaport Family Institute For Research In The Medical Sciences Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
KR20010080142A (ko) 1998-10-13 2001-08-22 후지야마 아키라 사이클릭 테트라펩티드 화합물 및 이의 용도
KR20020007398A (ko) 1999-05-03 2002-01-26 추후제출 히스톤 탈아세틸화효소의 억제
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
BR0014254A (pt) 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
KR20070053362A (ko) 1999-11-23 2007-05-23 메틸진, 인크. 히스톤 디아세틸라제의 억제제
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ525439A (en) 2000-09-29 2004-11-26 Topotarget Uk Ltd Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2002102323A2 (en) 2001-06-14 2002-12-27 Bristol-Myers Squibb Company Novel human histone deacetylases
JP4638148B2 (ja) 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US20040132643A1 (en) 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
AU2003219803B8 (en) 2002-02-15 2005-08-25 Sloan-Kettering Institute For Cancer Research Method of treating TRX mediated diseases
US20070060614A1 (en) 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20060276547A1 (en) 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
EP2266552A3 (en) 2002-03-04 2011-03-02 Merck HDAC Research, LLC Methods of inducing terminal differentiation
CN100566711C (zh) 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
EP1567142A4 (en) 2002-11-20 2005-12-14 Errant Gene Therapeutics Llc TREATMENT OF PULMONARY CELLS WITH HISTONE DEACETYLASE INHIBITORS
CN1839121A (zh) 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
CA2535806C (en) * 2003-08-26 2009-02-17 Aton Pharma, Inc. The use of hdac inhibitors for the treatment of cancer
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
US20090227674A1 (en) 2005-08-18 2009-09-10 Richon Victoria M Combination methods fo saha and targretin for treating cancer
EP1942884A4 (en) 2005-11-04 2010-01-06 Merck & Co Inc METHOD FOR THE TREATMENT OF CANCER WITH SAHA, CARBOPLATIN AND PACLITAXEL AND OTHER COMBINATION THERAPIES
CN101300015A (zh) 2005-11-04 2008-11-05 默克公司 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法
US20070197473A1 (en) 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer

Also Published As

Publication number Publication date
WO2006127321A2 (en) 2006-11-30
EP2292221A3 (en) 2011-08-10
US20080132575A1 (en) 2008-06-05
IL181070A0 (en) 2007-07-04
DOP2006000113A (es) 2006-10-31
AU2009201652B2 (en) 2011-10-06
KR20080113135A (ko) 2008-12-26
CA2580367A1 (en) 2006-11-30
US8288440B2 (en) 2012-10-16
ECSP077263A (OSRAM) 2007-04-26
MX2007002047A (es) 2007-04-12
PE20061390A1 (es) 2007-01-15
AU2010201359A1 (en) 2010-04-29
AR055953A1 (es) 2007-09-12
WO2006127319A2 (en) 2006-11-30
JP2011251985A (ja) 2011-12-15
MY144613A (en) 2011-10-04
EP1853245A2 (en) 2007-11-14
US8450372B2 (en) 2013-05-28
AU2006249440B2 (en) 2009-03-12
AU2009201652A1 (en) 2009-05-21
AU2009201650A1 (en) 2009-05-21
NI200700031A (es) 2008-03-03
EP2292221A2 (en) 2011-03-09
AU2006249440A1 (en) 2006-11-30
KR100993135B1 (ko) 2010-11-10
TWI365068B (en) 2012-06-01
CR8912A (es) 2008-02-21
US20100113829A1 (en) 2010-05-06
US8093295B2 (en) 2012-01-10
US20100112046A1 (en) 2010-05-06
TW200727892A (en) 2007-08-01
MA28804B1 (fr) 2007-08-01
KR20070062505A (ko) 2007-06-15
KR100884500B1 (ko) 2009-02-20
AU2009201650B2 (en) 2011-09-15
NZ553204A (en) 2011-09-30
TW201034660A (en) 2010-10-01
CA2580367C (en) 2012-08-21
AU2006249440C1 (en) 2009-08-13
JP2008519081A (ja) 2008-06-05
WO2006127319A3 (en) 2007-03-29
TWI415603B (zh) 2013-11-21
US20100119596A1 (en) 2010-05-13
BRPI0605893A (pt) 2007-12-18
WO2006127321A3 (en) 2007-03-22
NZ594669A (en) 2013-02-22
JP5308486B2 (ja) 2013-10-09

Similar Documents

Publication Publication Date Title
JP5308486B2 (ja) スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法
KR20090064400A (ko) Ｈｄａｃ 억제제 및 킬레이트화 가능한 금속 화합물 및 금속-ｈｄａｃ 억제제 킬레이트 착물의 약제학적 조성물
CN101080223B (zh) 辛二酰苯胺异羟肟酸制剂及其制备方法
US20100035991A1 (en) Amide base salts of saha and polymorphis thereof
WO2024175662A1 (en) Flavagline derivatives as ras inhibitors
RU2778508C1 (ru) Кристаллическая форма моноэтаноламин 3'-[(2Z)-2-[1-(3,4-диметилфенил)-1,5-дигидро-3-метил-5-оксо-4Н-пиразол-4-илиден]гидразино]-2'-гидрокси-[1,1'-бифенил]-3-карбоновой кислоты
HK1072362B (en) Methods of inducing terminal differentiation
HK1072362A1 (en) Methods of inducing terminal differentiation

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110412

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20120214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120511

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130208

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130223

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130430

R150 Certificate of patent or registration of utility model

Ref document number: 5264174

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250